Circulation Supplement Guide: What The Evidence Actually Cost

Circulation is not one thing and the research does not treat it as one. Three separate literatures get folded together on supplement labels, and a reader who keeps them apart will read almost every bottle in the category more accurately.

The first is arterial: blood reaching muscle, most often studied in intermittent claudication, where a measurable outcome exists in the distance somebody can walk before pain stops them. The second is venous: blood returning from the legs, studied in chronic venous insufficiency, where the outcomes are swelling, heaviness and leg volume. The third is cardiac: the heart as a pump, studied in heart failure, where the outcomes are exercise tolerance and symptom scores.

Those three have different plants, different trial designs and different evidence quality. A label that says supports healthy circulation is standing on all three at once without committing to any, which is legally permitted and informationally empty. The sections below take them one at a time.

Six literatures, routinely compressed into one sentence on a label.

Ginkgo is the most studied plant in this category and its evidence has moved in one direction over twenty-five years, which is downwards. An early meta-analysis found a benefit in claudication and was widely quoted. The Cochrane review that followed pooled fourteen trials in 739 participants and reached a more cautious conclusion.

The EGb 761 literature is worth separating from the rest, because it is one specific standardised extract rather than ginkgo in general. A standardised extract has a code, a defined marker content and a manufacturer, and a trial that used it is testing a specific product rather than a plant. That distinction is why a bottle saying ginkgo leaf tells you materially less than a bottle saying EGb 761.

The interaction record is the part of the ginkgo story most worth carrying away. A 2025 analysis of ginkgo interactions sets out the bleeding signal, and a systematic review of warfarin interactions places it alongside the other supplements that have been implicated. Anyone on an anticoagulant has a specific reason to raise ginkgo before taking it.

Three of the four records did not state a dose range in the portion retrieved, and this guide does not supply one.

Hawthorn is the clearest case in the category, and it is clear precisely because the trials used one standardised extract and published what they used. SPICE ran WS 1442 at 900 mg/day of WS 1442, in patients with LVEF 35% or below. HERB CHF ran 450 mg twice daily for six months, 120 ambulatory patients.

The Cochrane review pooled the earlier work and found benefit on symptom and exercise measures in chronic heart failure. A benefit-risk assessment of the same extract followed.

Two things follow for a reader holding a bottle. The first is arithmetic: 900 mg a day of a standardised extract is a substantial quantity of plant material, and a product that does not state an amount cannot be assumed to be anywhere near it. The second is context: those trials ran in people with diagnosed heart failure under supervision, which is not the population buying a wellness supplement, and a result does not automatically travel between populations either.

The venous literature is the most coherent part of this category and the least represented on supplement labels, which is an odd combination. The Cochrane review of horse chestnut seed extract restricted itself to mono-preparations, which is the right decision for a review and tells you something about how many products are not mono-preparations.

The Cochrane review of phlebotonics covers the class as a whole, and a 2026 appraisal of venoactive drugs compares named preparations against guideline positions. A systematic review of Centella asiatica found eight studies with unclear risk of bias, and a review of Ruscus in venous edema is narrative rather than systematic.

The practical reading is that this is the corner of the category where a specific named preparation at a specific dose has the best chance of doing something, and where unnamed blends have the least excuse for being unnamed. Horse chestnut in particular has been studied as a mono-preparation because it works or does not work on its own.

Four of these five records gave no dose range in the portion retrieved. That is a property of review abstracts rather than of the trials underneath them.

This is where the numbers get concrete, and it is worth reading slowly because the amounts are the part that surprises people. The six-month blueberry trial ran 75 g and 150 g freeze-dried equivalent per day — half a cup and one cup — for six months, n=115 in 115 people with metabolic syndrome. A wild blueberry trial in older adults ran 26 g freeze-dried wild blueberry powder supplying 302 mg anthocyanins per day.

Read those two doses again. One cup of freeze-dried blueberry equivalent a day, for six months. Twenty-six grams of wild blueberry powder a day, supplying 302 mg of anthocyanins. These are food quantities, not capsule quantities, and no dropper bottle in the world delivers them.

A grape seed extract meta-analysis reports on flow-mediated dilation, and the record notes that the effect varied with dose and duration without the figures appearing in the portion retrieved. Variation with dose is itself the finding worth carrying: it means the amount matters, which means a product that does not state one cannot be evaluated.

Products in this category frequently carry a metabolic framing alongside the circulation one, so the evidence belongs here even though it answers a different question. A dose-response meta-analysis of cinnamon pooled 24 trials and reported fasting glucose and HbA1c falling while insulin did not. A GRADE-assessed meta-analysis and a 2025 review cover the same ground more recently.

Cinnamon also carries the clearest ceiling in this guide, and it is a ceiling rather than a dose. The coumarin risk assessment sets a tolerable daily intake of tolerable daily intake 0.1 mg per kg body weight. Cassia cinnamon carries coumarin and Ceylon carries very little, so which species is in a product decides whether that ceiling is anywhere near relevant. Labels rarely say. A case report of a cinnamon supplement exists in the literature and is worth knowing about.

A Gymnema trial in impaired glucose tolerance ran 300 mg twice daily, fifteen patients per arm. A meta-analysis of chromium and an earlier review cover chromium, and a ginseng meta-analysis covers ginseng. None of those three records stated a dose range in the portion retrieved.

One clear dose, one clear ceiling, three records that did not state one.

Energy is the vaguest word on any supplement label, and the research behind it is correspondingly specific about something quite narrow. A meta-analysis of EGCG and energy expenditure reports effects on energy expenditure and fat oxidation at effects on fat oxidation reported at a 300 mg dose.

Energy expenditure is a measurement in a calorimeter. It is not the feeling of having more energy, which is what a buyer reads the word to mean, and the two are only loosely related. A product claiming to support overall energy is standing on a word whose research meaning and everyday meaning have drifted a long way apart.

A review of African mango trials is included here as the clearest example of the opposite problem: three trials, all poorly reported, and authors who call the effect unproven. A plant can have trials and still have no evidence, and telling the difference is most of what reading this literature consists of.

Two pieces of context belong at the end rather than the beginning. The USPSTF recommendation statement on supplements for cardiovascular disease and cancer prevention, with the evidence report behind it, is the most authoritative general position available and it is not enthusiastic. A 2026 analysis of American supplement use shows how many people take them anyway.

An analysis of FDA supplement warnings covers what has been found in products whose labels described their contents loosely or not at all, and a 2026 review of drug-induced liver injury includes herbal and dietary products as a recognised category. A critical appraisal of herbal remedy evidence is the best single piece on how to read a claim in this field at all.

Put together, the picture is neither the seller's nor the sceptic's. Several plants here have genuine published effects. Those effects were measured at amounts that food-scale or pharmaceutical-scale dosing achieves and that most retail products do not state. And the category has a documented problem with labels that describe their contents loosely, which is exactly the circumstance in which a printed amount becomes the most valuable thing on a package.